IL1B and Recurrent upper respiratory tract infections: Long-term systemic neutralization of IL-1β by Canakinumab may increase the risk of serious upper respiratory tract infections, gastrointestinal disorders and vertigo, and decrease the quality of life of both patients and informal caregivers2,9,10,29.